Market Insight: Psychedelic Funding Trends Q1 2026 Indicate Industry Momentum

The psychedelic industry saw a slight decrease in Q1 2026 funding, totaling $348M across 11 events, reflecting a potentially cautious investment environment. A substantial portion of this capital flowed to Compass Pathways, which is actively pursuing an FDA New Drug Application for psilocybin for treatment-resistant depression following positive Phase 3 readouts. This sustained investment in drug development and regulatory pathways by major players suggests ongoing efforts to bring psychedelic substances to market, which will likely shape future compliance landscapes for merchants.